{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T01:43:16Z","timestamp":1773020596022,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ejps.2020.105484","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T12:27:12Z","timestamp":1595334432000},"page":"105484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Population pharmacokinetics of phenobarbital in Caucasian patients with epilepsy"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4677-4784","authenticated-orcid":false,"given":"Paulo","family":"Teixeira-da-Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Santos-Buelga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Otero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105484_bib0001","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2125.1991.tb03971.x","article-title":"Population pharmacokinetics: theory and practice","volume":"32","author":"Aarons","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0002","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF03220012","article-title":"Sparse data analysis","volume":"18","author":"Aarons","year":"1993","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2020.105484_bib0003","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1382-6689(96)00055-5","article-title":"Population approaches\/sparse data analysis for human variability in kinetics and dynamics","volume":"2","author":"Aarons","year":"1996","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0004","unstructured":"Accord-UK Ltd, 2019. Phenobarbital Accord Tablets BP 30 mg. 2019. https:\/\/www.medicines.org.uk\/emc\/medicine\/24077\/SPC\/Phenobarbital+Tablets+BP+30mg\/ (accessed 12 January 2019)."},{"key":"10.1016\/j.ejps.2020.105484_bib0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1157\/13106681","article-title":"Interacciones medicamentosas: aproximaci\u00f3n para establecer y evaluar su relevancia cl\u00ednica","volume":"129","author":"Amariles","year":"2007","journal-title":"Med. Cl\u00edn."},{"key":"10.1016\/j.ejps.2020.105484_bib0006","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.2042-7158.1986.tb03083.x","article-title":"Comparison of fluorescence polarization immunoassay and high performance liquid chromatography for the quantitative determination of phenytoin, phenobarbitone and carbamazepine in serum","volume":"38","author":"Ashy","year":"1986","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0007","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2125.1994.tb04375.x","article-title":"Inhibition of phenobarbitone N\u2010glucosidation by valproate","volume":"38","author":"Bernus","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0008","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00003088-199529030-00005","article-title":"Geographical\/interracial differences in polymorphic drug oxidation","volume":"29","author":"Bertilsson","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2020.105484_bib0009","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00194954","article-title":"Determination of phenobarbitone population clearance values for South African children","volume":"48","author":"Botha","year":"1995","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0010","series-title":"BNF 67: British National Formulary: March 2014 - September 2014","year":"2014"},{"key":"10.1016\/j.ejps.2020.105484_bib0011","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02353487","article-title":"A population pharmacokinetic model for docetaxel (taxotere\u00ae): model building and validation","volume":"24","author":"Bruno","year":"1996","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2020.105484_bib0012","series-title":"Gu\u00eda Oficial De Pr\u00e1ctica Cl\u00ednica En Epilepsia","first-page":"111","article-title":"3.1. Tratamiento antiepil\u00e9ptico cr\u00f3nico en la infancia y en el adulto","author":"Campos","year":"2012"},{"key":"10.1016\/j.ejps.2020.105484_bib0013","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2125.2000.00237.x","article-title":"Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children","volume":"50","author":"Chen","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0014","unstructured":"Epilepsy Foundantion, 2018. Phenobarbital. https:\/\/www.epilepsy.com\/medications\/phenobarbital\/advanced(accessed 12 January 2019)."},{"key":"10.1016\/j.ejps.2020.105484_bib0015","unstructured":"European Medicines Agency, 2016. Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. 2020."},{"key":"10.1016\/j.ejps.2020.105484_bib0016","unstructured":"Food and Drug Administration, 2019. Population Pharmacokinetics Guidance for Industry. 2020."},{"key":"10.1016\/j.ejps.2020.105484_bib0017","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FTD.0b013e318030def0","article-title":"Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese","volume":"29","author":"Goto","year":"2007","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2020.105484_bib0018","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000457062","article-title":"Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data","volume":"8","author":"Grasela","year":"1985","journal-title":"Dev. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2020.105484_bib0019","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2125.2003.01849.x","article-title":"Development of a dosing strategy for enoxaparin in obese patients","volume":"56","author":"Green","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0020","series-title":"Anonymous Clinical Pharmacology of Anti-Epileptic Drugs","first-page":"2","article-title":"Statistical analysis of pharmacokinetic parameters in epileptic patients chronically treated with anti-epileptic drugs","author":"Guelen","year":"1975"},{"key":"10.1016\/j.ejps.2020.105484_bib0021","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1742-7843.2007.00061.x","article-title":"Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients","volume":"100","author":"Gunes","year":"2007","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejps.2020.105484_bib0022","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin. Pharmacokinetic"},{"key":"10.1016\/j.ejps.2020.105484_bib0023","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/clpt.1981.66","article-title":"Mechanism of valproate\u2010phenobarbital interaction in epileptic patients","volume":"29","author":"Kapetanovi\u0107","year":"1981","journal-title":"Clin. Pharmacol. Therapeutics"},{"key":"10.1016\/j.ejps.2020.105484_bib0024","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/ajcp\/80.5.686","article-title":"Evaluation of the Abbott TDx for the stat measurement of phenobarbital, phenytoin, carbamazepine, and theophylline","volume":"80","author":"Loomis","year":"1983","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ejps.2020.105484_bib0025","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s002280050703","article-title":"CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics","volume":"55","author":"Mamiya","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0026","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/fcp.12042","article-title":"Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach","volume":"28","author":"Marsot","year":"2014","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0027","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/fcp.12291","article-title":"Phenobarbital in intensive care unit pediatric population: predictive performances of population pharmacokinetic model","volume":"31","author":"Marsot","year":"2017","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0028","series-title":"The Treatment of Epilepsy, 4th Edn","first-page":"555","article-title":"Phenobarbital, primidone and other barbiturates","author":"Michelucci","year":"2016"},{"key":"10.1016\/j.ejps.2020.105484_bib0029","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/epi.14447","article-title":"Phenobarbital population pharmacokinetics across the pediatric age spectrum","volume":"59","author":"Moffett","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2020.105484_bib0030","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.ejps.2020.105484_bib0031","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/j.1552-4604.1982.tb02662.x","article-title":"Phenobarbital pharmacokinetics and bioavailability in adults","volume":"22","author":"Nelson","year":"1982","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0032","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00007691-198409000-00018","article-title":"Clinical evaluation of the Abbott TDx fluorescence polarization immunoassay analyzer","volume":"6","author":"Oeltgen","year":"1984","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2020.105484_bib0033","series-title":"A Clinical Guide","article-title":"Antiepileptic drug interactions","author":"Patsalos","year":"2013"},{"key":"10.1016\/j.ejps.2020.105484_bib0034","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejps.2020.105484_bib0035","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0036","unstructured":"Queensland Government. Using body mass index, 2017. https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0031\/147937\/hphe_usingbmi.pdf. (Accessed 26 September 2018)."},{"key":"10.1016\/j.ejps.2020.105484_bib0037","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/epi4.12268","article-title":"Brief history of anti\u2010seizure drug development","volume":"3","author":"Rho","year":"2018","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.ejps.2020.105484_bib0038","series-title":"Antiepileptic Drugs, 4th Edn","first-page":"621","article-title":"Valproic acid. Interaction with other drugs","author":"Scheyer","year":"1995"},{"key":"10.1016\/j.ejps.2020.105484_bib0039","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/PCC.0b013e31825bbbc2","article-title":"Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia","volume":"14","author":"Shellhaas","year":"2012","journal-title":"Pediatr. Crit. Care. Med."},{"key":"10.1016\/j.ejps.2020.105484_bib0040","unstructured":"Simon, N., 2006. Pharmacocin\u00e9tique De Population: introduction \u00c0 Nonmem. Solal, Marseille."},{"key":"10.1016\/j.ejps.2020.105484_bib0041","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2165\/00003088-199631030-00004","article-title":"Clinically significant pharmacokinetic drug interactions with carbamazepine. An update","volume":"31","author":"Spina","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2020.105484_bib0042","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bcp.13400","article-title":"Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children","volume":"84","author":"van Dijkman","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0043","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00228-014-1778-7","article-title":"Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients","volume":"71","author":"Vu\u010di\u0107evi\u0107","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0044","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ejps.2009.09.017","article-title":"The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling","volume":"38","author":"Vucicevic","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105484_bib0045","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","article-title":"In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)","volume":"52","author":"Wen","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0046","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/epi.12026","article-title":"How phenobarbital revolutionized epilepsy therapy: the story of phenobarbital therapy in epilepsy in the last 100 years","volume":"53","author":"Yasiry","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2020.105484_bib0047","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s002280050423","article-title":"Detection of a drug\u2013drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling","volume":"54","author":"Yukawa","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105484_bib0048","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2710.1992.tb01301.x","article-title":"Influence of age and co-medication on steady-state phenobarbital serum level-dose ratios in Japanese paediatric patients","volume":"17","author":"Yukawa","year":"1992","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2020.105484_bib0049","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2710.2006.00712.x","article-title":"Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using non-linear mixed effects model approach","volume":"31","author":"Yukawa","year":"2006","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2020.105484_bib0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2710.2005.00619.x","article-title":"Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants","volume":"30","author":"Yukawa","year":"2005","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2020.105484_bib0051","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1365-2710.2010.01220.x","article-title":"Population pharmacokinetics of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants: an update","volume":"36","author":"Yukawa","year":"2011","journal-title":"J. Clin. Pharm. Ther."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720302736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720302736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:53:38Z","timestamp":1760529218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098720302736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":51,"alternative-id":["S0928098720302736"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105484","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of phenobarbital in Caucasian patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105484"}}